SynerGene Therapeutics, Inc.
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SynerGene Therapeutics, Inc.
PharmAbcine Seeks Australian Fast Track For Glioblastoma Candidate
Following an initial clinical study in South Korea, PharmAbcine is progressing with Phase IIa plans in Australia for its anticancer antibody tanibirumab. The South Korean biotech expects to benefit from the country's ‘outstanding’ clinical trial system and is aiming to initially launch the drug in Australia through a fast-track approval system without a Phase III program.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SynerGene Therapeutics, Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice